



Daiichi-Sankyo

RANBAXY

Press Release

Ranbaxy to Market Daiichi Sankyo's Innovative Products in Malaysia

Strategic Alliance Harnesses Synergies in ASEAN

December 21, 2011, Tokyo, Japan and Gurgaon, India - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced a synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the companies' second marketing synergy in the ASEAN region.

Ranbaxy will market Cravit[®] (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical Sdn Bhd (hereafter, First Pharma) in Malaysia. Daiichi Sankyo and First Pharma have agreed to transfer the marketing rights of Cravit[®] (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo's marketing partner for other products (except Cravit[®]) it had in-licensed from Daiichi Sankyo.

"We are pleased to announce another synergistic business development with Ranbaxy in ASEAN," said Joji Nakayama, President & CEO of Daiichi Sankyo. "Our previous collaboration, in Singapore, has already proved Ranbaxy's marketing excellence in this strongly emerging region. We will continue to explore further initiatives with Ranbaxy to serve diversifying medical needs."

Commenting on the development, **Arun Sawhney, CEO & Managing Director of Ranbaxy**, said, *"Ranbaxy has been acknowledged as a premier branded generics company in Malaysia and is well known for its innovative marketing strategies and professional approach. This is in addition to Ranbaxy's reputation of providing high quality, safe and efficacious products to customers, since 1984. The synergy between Ranbaxy and Daiichi Sankyo will allow us to introduce innovator products from Daiichi Sankyo, complementing our own portfolio of branded generics to bring a wider range of medicines to Doctors and Patients. I am confident that our Malaysian team will enhance the level of customer satisfaction through this synergy."*

Arun Sawhney

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. Originally discovered by Daiichi Sankyo, levofloxacin was first launched in Japan in 1993 under the brand name Cravit[®]. Levofloxacin is currently available in more than 120 countries worldwide.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

For further information, please contact:

**Daiichi Sankyo Company,
Limited
3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo 103-8426,
Japan**

Toshiaki Sai
Corporate Officer - Corporate Communications

Masaya Tamae
Senior Director - Public Relations
Tel: +81-3-6225-1126

Shigemichi Kondo
Senior Director - Investor Relations
Tel: +81-3-6225-1126

S Sai

Ranbaxy Laboratories Limited
Plot 90, Sector 32, Gurgaon
Haryana 122001, India

Ramesh L. Adige
President - Corporate Affairs and
Global Corporate Communications
email: ramesh.adige@ranbaxy.com
Tel: +91-124-4135000

Raghu Kochar
Director-Corporate Communications
email: raghu.kochar@ranbaxy.com
Tel: +91-124-4135141
Mobile: 9811617256

Krishnan Ramalingam
General Manager-Corporate Communications
email: krishnan.ramalingam@ranbaxy.com
Tel: +91-124-4135143
Mobile: 9810042540

Sean